FDA will convene the Pharmacy Compounding Advisory Committee (PCAC) on July 23-24, 2026, to discuss seven peptides for potential inclusion on the 503A bulks list. An additional five peptides will be ...
Study on compounded GLP-1s uncovers use of additives and questionable sterility practices, revealing legally ‘murky’ area.
You’ve probably seen compounding making headlines recently, and not for the right reasons. From so-called “personalized” GLP-1s flooding the market to telehealth startups touting hormone “rebalancing” ...
In March, Pharmaceutical Executive reported on Eli Lilly’s efforts to push back against the availability of compounded GLP-1 ...
With Health Secretary Robert F. Kennedy Jr. declaring himself “a big fan of peptides,” the FDA has arranged an advisory ...
Health Secretary Robert F. Kennedy Jr. is a self-professed “big fan” of peptides. They have grown in popularity for wellness ...
The FDA is set to review whether compounding pharmacies can produce seven peptides that have not undergone full safety and efficacy trials. Supporters, including Health Secretary Robert F. Kennedy Jr.
A month ago, Health Secretary Kennedy said his agency would soon give compounding pharmacies the greenlight to make the products, which have exploded in popularity despite a lack of data.
An exclusive accreditation program for APC members—priced at up to half the cost of other accreditations. One accreditation. Real compliance. Less frustration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results